CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

• Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
  – Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation
  – Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses
• Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron
• Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well as access to novel classes of antigens and antigen discovery platforms
• Launched fully owned subsidiary, CureVac RNA Printer GmbH, to accelerate development of The RNA Printer® with dedicated infrastructure and experienced management
• Executed contract with German government for pandemic preparedness together with GSK, providing access to developed vaccines and CureVac’s manufacturing capacity
• Cash position of €811.5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoV

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2021 and provided a business update.